Order Article Reprints

Edelman-Klapper H, Rabinowitz KM, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, et al. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines. 2023; 11(7):1263. https://doi.org/10.3390/vaccines11071263

Edelman-Klapper, Hadar, Keren Masha Rabinowitz, Eran Zittan, Ariella Bar-Gil Shitrit, Idan Goren, Irit Avni-Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran, Henit Yanai, and et al. 2023. "Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases" Vaccines 11, no. 7: 1263. https://doi.org/10.3390/vaccines11071263

Edelman-Klapper, H., Rabinowitz, K. M., Zittan, E., Bar-Gil Shitrit, A., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Broitman, Y., Ben Zvi, H., Perets, T.-T., Eliakim, R., Barkan, R., ... Dotan, I., on behalf of the REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. (2023). Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines, 11(7), 1263. https://doi.org/10.3390/vaccines11071263